DNA Repair Communiqué II
In this DNA Repair Communiqué II we delve deeper into the topic...
Read More
First XP-V Patient Treated in CLINUVEL DNA Repair Study
CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...
Read More
Change of Director's Interest Notice
Melbourne, Australia, 23 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
ACTH Manufacturing Update
CLINUVEL is progressing scaled manufacturing of adrenocorticotropic hormone (ACTH) under current Good...
Read More
Afamelanotide in stroke (AIS) – positive preliminary results
CLINUVEL today released positive preliminary results from its pilot study (CUV801) in...
Read More
Change of Director's Interest Notice
Melbourne, Australia, 02 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
CEO letter
On 24 February, the world plunged into instability, initiated by delusional warfare...
Read More
CLINUVEL Reports Record December Half Year Operating Profit
Melbourne, Australia, 23 February 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Appendix 4D - ASX Listing Rule 4.2A.3 Half Yearly Report
Melbourne, Australia, 23 February 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Financial Results Half Year Ended, 31 December 2021
CLINUVEL PHARMACEUTICALS LTD announced today the financial results for the half year...
Read More
DNA Repair Communiqué I
This first Communiqué in a series on DNA forms an introductory foundation,...
Read More
CLINUVEL Expands DNA Repair Program with 2nd DNA Repair Study
CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...
Read More
Appendix 4C & Activity Report
Melbourne, Australia, 31 January 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More